Your browser doesn't support javascript.
loading
Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study.
Schräder, Nicholas H B; Gorell, Emily S; Stewart, Roy E; Duipmans, José C; Harris, Nicole; Perez, Victoria A; Tang, Jean Y; Wolff, André P; Bolling, Marieke C.
Afiliação
  • Schräder NHB; Department of Dermatology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. n.h.b.schrader@umcg.nl.
  • Gorell ES; Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Stewart RE; Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA.
  • Duipmans JC; Department of Health Sciences, Community and Occupational Medicine, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Harris N; Department of Dermatology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
  • Perez VA; Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA.
  • Tang JY; Columbia University School of Medicine, New York, NY, USA.
  • Wolff AP; Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA.
  • Bolling MC; Anaesthesiology Pain Centre, Department of Anaesthesiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Orphanet J Rare Dis ; 16(1): 377, 2021 09 06.
Article em En | MEDLINE | ID: mdl-34488820
BACKGROUND: Epidermolysis bullosa (EB) patient anecdotes and case reports indicate that cannabinoid-based medicines (CBMs) may alleviate pain and pruritus and improve wound healing. CBM use has not been characterized in the EB patient population. OBJECTIVES: To evaluate CBM use among EB patients, including CBM types, effects on symptoms (e.g., pain and pruritus), disease process (e.g., blistering, wounds, and inflammation), well-being (e.g., sleep, appetite) and concomitant medications. METHODS: English-speaking EB patients or caregivers completed an online international, anonymous, cross-sectional survey regarding CBM use. Respondents reported the types of CBMs, subsequent effects including perceived EB symptom alteration, changes in medication use, and side effects. RESULTS: Seventy-one EB patients from five continents reported using or having used CBMs to treat their EB. Missing question responses ranged between 0 (0%) and 33 (46%). Most used more than one CBM preparation (mean: 2.4 ± 1.5) and route of administration (mean: 2.1 ± 1.1). Topical and ingested were the most common routes. Pain and pruritus were reported retrospectively to decrease by 3 points (scale: 0-10; p < 0.001 for both) after CBM use. Most reported that CBM use improved their overall EB symptoms (95%), pain (94%), pruritus (91%) and wound healing (81%). Most participants (79%) reported decreased use of pain medications. The most common side-effect was dry mouth (44%). CONCLUSIONS: CBMs improve the perception of pain, pruritus, wound healing, and well-being in EB patients and reduced concomitant medication use. Nevertheless, a direct relation between the use of CBMs and reduction of the above-mentioned symptoms cannot be proven by these data. Therefore, future controlled studies using pharmaceutically standardised CBM preparations in EB are warranted to delineate the risks and benefits of CBMs.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Canabinoides / Epidermólise Bolhosa Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Canabinoides / Epidermólise Bolhosa Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article